Showing results (421-430 of 656) with videos related to

Sort By:
Pageof 66
Scientific Reports|February 17, 2026
Intercostal thickening fraction adds no value to diaphragm thickening fraction in healthy subjects undergoing noninvasive ventilationClara Hoermann, Luisa Sophie Drotleff, Burcu Link, et al.
International Journal of Molecular Sciences|September 28, 2023
Flagellin-Induced Immune Response in Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesGoekhan Yuecel, Xiaobo Zhou, Linda Terkatz, et al.
Clinical and Translational Science|May 19, 2026
CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCIDiona Gjermeni, Sofia Szabó, Viktoria Anfang, et al.
Endocrine|July 13, 2026
Thyroid function and outcomes in heart failure with mildly reduced ejection fraction: insights from a large, retrospective registryMohammad Abumayyaleh, Ibrahim Akin, Michelle Goertz, et al.
Life (Basel, Switzerland)|July 29, 2023
An Activation-Specific Anti-Mac-1 Designed-Ankyrin-Repeat-Protein Attenuates Colitis in MiceIstvan Bojti, Qianqi Wang, Tibor Bojti, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 31, 2002
Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1Michiel Voskuil, Niels van Royen, Imo E Hoefer, et al.
Atherosclerosis|July 26, 2005
Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytesImo E Hoefer, Sebastian Grundmann, Niels van Royen, et al.
American Heart Journal|May 17, 2011
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndromeC Michael Gibson, Jessica L Mega, Paul Burton, et al.
Thrombosis and Haemostasis|March 12, 2009
Desmoteplase in acute massive pulmonary thromboembolismUlrich Tebbe, Peter Bramlage, Andreas Graf, et al.
Nature Communications|February 8, 2018
A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defenseDennis Wolf, Nathaly Anto-Michel, Hermann Blankenbach, et al.
Pageof 66